Understand the source comparison
Best Research Peptides for Metabolic Syndrome Research: Mechanism Comparison
GLP-1 Agonists (Semaglutide) GLP-1 receptor activation → delayed gastric emptying, reduced appetite Fasting glucose, triglycerides, waist circumference 0.25–2.4mg weekly SC Subcutaneous injection Gold standard for multi-component metabolic improvement with ext
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- GLP-1 Agonists (Semaglutide)
- GLP-1 receptor activation → delayed gastric emptying, reduced appetite
- Fasting glucose, triglycerides, waist circumference
- 0.25–2.4mg weekly SC
- Subcutaneous injection
- Gold standard for multi-component metabolic improvement with extensive clinical validation. Best choice when weight reduction is a primary endpoint
- Dual Agonists (Tirzepatide)
- GIP/GLP-1 receptor co-activation → enhanced insulin sensitivity in adipose tissue
- Fasting glucose, HbA1c, triglycerides, HDL, waist circumference
- 2.5–15mg weekly SC
- Strongest effect size for simultaneous glucose and lipid correction. Ideal for studies requiring large delta changes in multiple biomarkers within 12–16 weeks
- Mitochondrial Peptides (MOTS-c)
- AMPK activation → improved glucose uptake independent of insulin
- Fasting glucose, insulin resistance (HOMA-IR)
- 5–15mg 3x weekly SC or intranasal
- SC injection or nasal spray
- Mechanistically distinct from receptor agonists. Best suited for aging-related metabolic dysfunction studies where mitochondrial capacity is the target
- Growth Hormone Secretagogues (GHRP-2)
- Pulsatile GH release → lipolysis, visceral fat reduction
- Waist circumference, triglycerides, HDL
- 100–300mcg 2–3x daily SC
- Produces body composition changes without dietary intervention. Valuable for isolating adipose tissue effects from caloric intake variables